MLND News and Press, Millendo Therapeutics From 01/05/21

– Further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, not planned following initial review of data from Phase 1 clinical study – – Company exploring expanded range of strategic alternatives to maximize its assets – ...

Millendo Therapeutics (MLND): Q3 GAAP EPS of -$0.34 beats by $0.12.Cash, cash equivalents and restricted cash were $43.8 million at September 30, 2020, compared to $63.5 million at December 31, 2019.Press Release For further details see: Millendo Therapeutics EPS beats by $0.12

– Phase 1 clinical trial underway for MLE-301, a selective NK3R antagonist being studied for the treatment of vasomotor symptoms (VMS) in menopausal women – Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily foc...

Spruce Biosciences has filed to raise $75 million in an IPO. The firm is developing treatments for rare endocrine disorders. Early trial results have been impressive and the IPO appears reasonably priced, so is worth a look for long-term hold life science investors. For furt...

Millendo Therapeutics (MLND) announces dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301. The first-in-human trial is designed to evaluate the safety and tolerability of MLE-301.“We are pleased to ad...

– First subject dosed with MLE-301, for the treatment of vasomotor symptoms (VMS) in menopausal women – – Phase 1 study will evaluate safety, pharmacokinetics and preliminary efficacy – Millendo Therapeutics, Inc. (Nasdaq: MLND), a cli...

Millendo Therapeutics (NASDAQ: MLND ) : Q2 GAAP EPS of -$0.56 misses by $0.01 . More news on: Millendo Therapeutics, Inc., Earnings news and commentary, , Read more ...

– Phase 1 clinical trial to initiate in 3Q20 for MLE-301, a selective NK3R antagonist being studied for the treatment of vasomotor symptoms (VMS) in menopausal women – Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focus...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the...

Millendo slumps ( MLND -13.5% ) on modestly higher volume after the company announced that it will be terminating development of nevanimibe for congenital adrenal hyperplasia (CAH). More news on: Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...